Academic
Publications
Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer

Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer,10.1007/s00280-010-1432-8,Cancer Chemotherapy and Pharmacology,D

Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer   (Citations: 2)
BibTex | RIS | RefWorks Download
D. Takahari, T. Hamaguchi, K. Yoshimura, H. Katai, S. Ito, N. Fuse, T. Kinoshita, H. Yasui, M. Terashima, M. Goto, N. Tanigawa, K. Shiraohttp://academic.research.microsoft.com/io.ashx?type=5&id=32516409&selfId1=0&selfId2=0&maxNumber=12&query=
Purpose  To evaluate the feasibility of S-1 plus cisplatin as adjuvant chemotherapy for stage III gastric cancer after curative resection. Methods  Japanese patients with stage III gastric cancer who underwent gastrectomy with D2 lymph node resection were enrolled. Treatment consisted of 3 cycles of S-1 (80 mg/m2/day, b.i.d.) for 21 days followed by a 14-day rest, and cisplatin (60 mg/m2 iv) on day 8. After that, S-1 monotherapy was given on days 1–28 every 6 weeks until 1-year postsurgery. After protocol amendment, the first chemotherapy cycle consisted of S-1 monotherapy; cisplatin was added to cycles 2, 3, and 4, followed by S-1 monotherapy up to 1-year postsurgery. The primary endpoint was the completion rate of three cycles of S-1 plus cisplatin. Results  A total of 63 enrolled patients have been evaluated. Grade 3/4 toxicities included neutropenia (40%), anorexia (28%), and febrile neutropenia (4%) before protocol amendment (n = 25), and neutropenia (37%), anorexia (8%), and febrile neutropenia (3%) after amendment implementation (n = 38). Excluding ineligible cases, treatment completion rates were 57% (12/21) before and 81% (30/37) after the protocol amendment. Conclusions  The amended S-1 plus cisplatin is more feasible than the original protocol because of early dose reduction of S-1 prior to cisplatin addition and greater recovery time from surgery prior to cisplatin. This treatment should be considered as a feasible experimental arm for the next postoperative adjuvant phase III trial.
Journal: Cancer Chemotherapy and Pharmacology - CANCER CHEMOTHER PHARMACOL , vol. 67, no. 6, pp. 1423-1428, 2011
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
Sort by: